

20 June 2023

ASX Announcement

Results of General Meeting

Firebrick Pharma Limited (ASX:FRE) (**Company** or **Firebrick**) advises it held its General Meeting today, at 11.00am (AEST).

The resolutions were voted in accordance with the Notice of General Meeting previously advised to the Australian Securities Exchange with all resolutions being passed on a poll.

Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick Pharma

Firebrick is a pharmaceutical company founded with the mission to commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold and a second patent family covering the prevention of pandemic viral diseases, including COVID-19. The Company also has a third patent family covering the Nasodine formulation, which has been granted in Australia. Firebrick is currently completing a second Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals. Positive Phase 3 trial results will also be important for securing regulatory approvals and partnerships in major markets outside Australia.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com

Disclosure of Proxy Votes

Firebrick Pharma Limited

General Meeting

Tuesday, 20 June 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Ratification of Tranche 1 Placement Shares	P	62,761,321	62,201,936 99.11%	308,103 0.49%	10,402	251,282 0.40%	62,503,218 99.51%	308,103 0.49%	10,402
2 Issue of Tranche 2 Placement Shares to Related Party – Stephen Goodall	P	37,865,727	37,460,935 98.93%	152,897 0.40%	9,524	251,895 0.67%	37,762,830 99.60%	152,897 0.40%	9,524
3 Issue of Tranche 2 Placement Shares to Related Party – Peter Molloy	P	37,865,727	37,460,935 98.93%	152,897 0.40%	9,524	251,895 0.67%	37,762,830 99.60%	152,897 0.40%	9,524

